Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of British Columbia

$50,000.00

Redesigning SARS CoV-2 spike protein to improve immunization - COVID-19_x000d_ _x000d_

EF 2020-21

Résumé
The ongoing COVID-19 pandemic continues to pose enormous health and economic challenges, highlighting the urgent need for a vaccine that prevents further spread of SARS-CoV-2. The receptor binding domain (RBD) of SARS-CoV-2' s spike protein S is a target for vaccine development because it initiates entry of the virus into host cells. However, key neutralizing epitopes in the RBD are only transiently exposed due to the samplings of "closed" S conformations that hide these epitopes from the humoral immune system. Our goals are to (i) delineate structural mechanisms leading to exposures of key epitopes in the homo-trimeric state of the SARS-CoV-2 protein S and (ii) exploit these insights in the engineering of S variants that improve immunogenicity through preservation of neutralization-sensitive conformational and quaternary epitopes. We will achieve this in a multidisciplinary approaches that draws from the expertise present in the research team and our partner. Specifically, we will first employ computational molecular modeling and simulations to design variants that stabilize "open'" states with exposed antigenic regions in RBD and its surroundings (Gsponer Lab). We will then express, purify, characterize the desired structural effects of the computationally designed variants with the help of single particle Cryo-EM (Subramaniam lab). Finally, in collaboration with our biotech partner AbCellera, we will use well-characterized and structurally-validated variants for immunization of humanized mice and test neutralizing activities of induced anti-sera and antibodies. Support for the proposed research will enable us to establish a pipeline for the engineering and structural characterization of new S protein variants and the subsequent characterization of the immunogenicity of these designed variants.
Programme
Alliance Grants
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
554620-2020
Name nom
Gsponer, Joerg
Department département
Biochemistry and Molecular Biology
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Redesigning SARS CoV-2 spike protein to improve immunization - COVID-19_x000d_ _x000d_
Keyword
NSERC
Application summary
The ongoing COVID-19 pandemic continues to pose enormous health and economic challenges, highlighting the urgent need for a vaccine that prevents further spread of SARS-CoV-2. The receptor binding domain (RBD) of SARS-CoV-2' s spike protein S is a target for vaccine development because it initiates entry of the virus into host cells. However, key neutralizing epitopes in the RBD are only transiently exposed due to the samplings of "closed" S conformations that hide these epitopes from the humoral immune system. Our goals are to (i) delineate structural mechanisms leading to exposures of key epitopes in the homo-trimeric state of the SARS-CoV-2 protein S and (ii) exploit these insights in the engineering of S variants that improve immunogenicity through preservation of neutralization-sensitive conformational and quaternary epitopes. We will achieve this in a multidisciplinary approaches that draws from the expertise present in the research team and our partner. Specifically, we will first employ computational molecular modeling and simulations to design variants that stabilize "open'" states with exposed antigenic regions in RBD and its surroundings (Gsponer Lab). We will then express, purify, characterize the desired structural effects of the computationally designed variants with the help of single particle Cryo-EM (Subramaniam lab). Finally, in collaboration with our biotech partner AbCellera, we will use well-characterized and structurally-validated variants for immunization of humanized mice and test neutralizing activities of induced anti-sera and antibodies. Support for the proposed research will enable us to establish a pipeline for the engineering and structural characterization of new S protein variants and the subsequent characterization of the immunogenicity of these designed variants.